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Summary
AIMS OF THE STUDY: Addiction associated with pre-
scription opioids is increasing worldwide, including
Switzerland. We aimed (1) to determine whether the
prevalence and incidence of opioid therapy at an emer-
gency department (ED) in Switzerland has changed over
five years and (2) to characterise consultations with inci-
dent opioid prescription.
METHODS: In this retrospective chart review, pre-existing
opioid treatment and new prescriptions at the ED of Bern
University Hospital “Inselspital”, Switzerland, between
2013 and 2017 were identified from the ED documentation
system. Patients already taking opioids before presenta-
tion (prevalent opioid use) were distinguished from opioid-
naïve patients who were prescribed opioids for the first
time (incident opioid prescription) and relative numbers in
every half year from 2013 to 2017 were calculated. Demo-
graphic and consultation characteristics were analysed to
determine factors associated with incident opioid prescrip-
tion.
RESULTS: Within the observation period, 199,299 pa-
tients consulted the ED. Of those, 4.95% (95% confidence
interval [CI] 4.86–5.05, n = 9868) were using opioids on
admission. Nearly 7.07% of them (95% CI 6.57–7.58, n
= 698), 0.35% of the complete sample, were prescribed
additional opioids. Incident opioid prescription for opioid-
naïve patients was found in 2.26% of patients (95%
2.19–2.32, n = 4499). The relative number of prevalent
opioid users did not show a significant (p = 0.163) asso-
ciation with time (categorised in half years) when adjust-
ed for the potential confounders age group, trauma, the in-
teraction of trauma and age group, other chief complaint,
type of admission and time of admission. Incident opioid
prescriptions significantly decreased over the study period
(slope = −0.041% per half year, standard error = 0.012%,
p = 0.007). The trend persisted after adjustment for the
abovementioned potential confounders. Consultations re-
sulting in opioid prescription were significantly associated
with older age, musculoskeletal disorders and trauma (p
<0.05).
CONCLUSIONS: Opioid prescriptions in a Swiss ED de-
creased between 2013 and 2017. Although this might be
a sign of awareness of the risks of opioid prescription, the
conclusion is derived from a single centre study and the
observed trend warrants confirmation by data from other
sources.
Keywords: opioid prescription, opioid analgesics, opioid
related-disorders, opiate dependence, pain management,
emergency service
Introduction
Pain is the most common motive for seeking medical care,
accounting for over half of the chief complaints in emer-
gency departments (EDs) [1]. Opioid use disorders are
estimated to have increased worldwide by 50% between
1990 and 2016 [2]. In the USA, opioid addiction has
reached epidemic proportions, with 18,238 opioid-related
deaths; in 2016, opioids were the fifth leading cause of
death in men aged between 15 and 49 years [2, 3]. Patients
discharged from the ED after an opioid overdose show in-
creased mortality, particularly in the following 2 days [4].
In 2015, 36.4% of the population above 12 years in the
USA used opioids and it was estimated that addiction as-
sociated with prescription opioids concerned 0.7% [5, 6].
The same percentage (0.7%) of the global population aged
15–64 years was assessed as misusing prescription drugs
in 2016 [7].
In 2015, Switzerland was the world’s seventh largest con-
sumer of opioids per capita [8] and the consumption of opi-
oids in Switzerland increased by 100% between 2006 and
2013 [9]. An analysis of health insurance data of one of
the major health insurers in Switzerland found that 14.3%
of the 2,561,558 insured patients (about 29% of the Swiss
population) made opioid claims between 2006 and 2014
[10].
In an analysis of 5308 young adult men from the Swiss co-
hort study on substance use risk factors, non-medical use
of prescription opioids was strongly associated with trau-
matic events such as traffic accidents, earthquakes, severe
illness or injury [11]. Most patients facing such events will
be treated in an ED. Conversion to persistent opioid use
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has been shown to increase in patients receiving an opioid
prescription in the ED [12].
Information about the prevalence and characteristics of pa-
tients who are taking or receiving opioids and consult an
ED may be useful in increasing clinical awareness and
in providing data for regional and national policymakers.
Furthermore, information about trends in opioid prescrip-
tion in recent years could provide information that might
be exploited in interventions to reduce opioid prescrip-
tions. Thus, we aimed (1) to determine the prevalence
of opioid-consuming patients and prescriptions at the ED
over the last 5 years and (2) to characterise consultations
with first time (incident) opioid prescription.
Methods
Study design, site and period
This study was a retrospective data analysis at the ED
of Bern University Hospital – with a catchment area of
two million people, and about 45,000 ED consultations per
year [13]. The study period was set from 1 January 2013 to
31 December 2017.
Eligibility criteria
All patients registered in the ED documentation system
E-Care (E-Care, ED 2.1.3.0, Turnhout, Belgium) between
2013 and 2017 were included in the analysis if they were
at least 16 years of age at the time of their presentation.
The records of patients who had been prescribed at least
one opioid (defined below) at either presentation or dis-
charge were further analysed in full text to determine the
incident and prevalent opioid use.
Definition of opioids
Opioids were defined as any medication with a code start-
ing with N02A, i.e., opioid analgesics, as defined in the
Anatomical Therapeutic Chemical (ATC) classification
system [14].
Data collection and extraction
On presentation at the ED, every patient receives a case
identification number, which is used for the recordings in
E-Care and further codified data analysis. Demographic
(age, gender) and health-related data of ED patients was
transferred into a database. The chief complaint and the
triage category are routinely registered by specially trained
nurses when the patient is admitted. The medication was
screened for opioids as defined above. The E-Care in-
terface is used for recording medication on presentation
and discharge. The two relevant fields were automatically
checked for relevant entries. These entries were made by
physicians during their routine work and were used to
identify patients who were either receiving opioids on ar-
rival or were discharged on opioids. The ED medical re-
ports of the identified consultations (opioid prescription on
arrival or discharge) were analysed in full text (by SW) to
determine the parameters: “prevalent opioid use” (consul-
tations with at least one opioid on arrival), “incident opioid
prescription in opioid-naïve patients” (consultations with a
newly prescribed opioid without documented opioid intake
on arrival) and “additional opioid prescription” (new opi-
oid substance, not an increase in the dose), using an ab-
straction form. The extractor was blinded to the study year.
For quality control, the stored medication fields of 200 ran-
domised consultations were manually checked for opioid
medication and compared with the automatic extraction
procedure. For training and validity purposes, the abstrac-
tor (SW) was briefed and the two variables “incident” and
“additional” opioid prescription were manually coded and
compared by two investigators (SW and MM) using 200
randomised consultations involving opioids. Cohen’s kap-
pa was calculated to test interrater reliability. A Cohen’s
kappa >0.800 was defined as an indicator for “high” agree-
ment.
Potential predictor variables
Year of admission, gender, age, reason for admission (chief
complaint), type of admission, triage according to the
Swiss triage scale [15] and revisits within 6 months were
considered potential predictor variables for incident opioid
prescription. These variables are all routinely stored in the
ED documentation system.
Ethical considerations
The study was performed in accordance with Swiss law.
The Bern ethics committee registered the study as a quality
control study (Req-2019-00593) and waived the need for
informed consent.
Statistical analysis
The statistical analysis was performed with Stata® 13.1
(StataCorp, The College Station, Texas, USA). The study
period was divided in into ten time intervals, each of 6
months (half year; first half of 2013 to the second half of
2017). The relative number of the target parameters (in-
cident and prevalent opioid prescription) was determined
and presented, accompanied by its 95% confidence inter-
val (CI) in total and in each timespan: for example, the
number of consultations with newly prescribed opioids per
half year divided by the total number of consultations in
the studied half year. The association of opioid prescription
(incident and prevalent) and time (half year) was tested us-
ing a chi-square test. In addition, the chi-square test for a
linear trend – including the slope and standard error of the
trend (Stata’s – ptrend command) – was used to test for a
trend over the study period and presented within a scatter
plot of the half year and the proportion. Associations of po-
tential predictor variables with any of the target parameters
were tested using a chi-square test. All potential predictor
variables were presented as a proportion accompanied by
the absolute number. For multivariable analysis, adjusted
proportions with 95% CIs of incident and prevalent opioid
prescription were obtained through multivariable logistic
regression analysis, in order to ensure that potential differ-
ences in proportions were not caused by identified possi-
ble confounders – including all variables that had shown at
least very weak evidence (p <0.2) for an association with
incident opioid prescription as potential confounders. In
addition, an interaction effect between age group and trau-
ma was implemented in the logistic regression model.
A p-value of <0.05 was considered significant. No formal
sample size calculation was performed but all eligible con-
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sultations were included in the study. There was no adjust-
ment for multiple hypothesis testing.
Results
Agreement was high for interrater values to determine opi-
oid prescription on presentation or discharge (Cohen’s kap-
pa = 0.960), newly prescribed (incident) opioid prescrip-
tion (Cohen’s kappa = 0.952), as well as additional opioid
prescription (Cohen’s kappa = 0.852).
Between January 2013 and December 2017, 206,021 pa-
tients were registered at the ED (fig. 1). Consultations with
missing administrative information or consultations of pa-
tients below 16 years of age were excluded; thus, entries
from 199,299 consultations were available for data analy-
sis.
In 5 years, 14,367 consultations had at least one opioid
documented on presentation or discharge (7.21%, 95% CI
7.10–7.32%). Around two thirds of these patients (n =
9868) were taking opioids at the time of presentation at the
ED (prevalent opioid use: 4.95%, 95% CI 4.86–5.05%),
and one third of the patients (n = 4499) were opioid naïve
and were prescribed opioids for the first time (incident opi-
oid prescription: 2.26%, 95% CI 2.19–2.32%). In 7.07%
of patients (95% CI 6.57–7.58%), additional opioids were
prescribed to patients already under opioid medication
(0.35%, 95% CI 0.32–0.38% of all consultations).
Associations with incident opioid prescription
Characteristics of patients with newly prescribed opioids
are shown in table 1. In comparison with patients without
incident opioid prescriptions, significant differences be-
tween the two groups were found for the age of the pa-
tients, type and time of admission, triage allocation and the
chief complaint (all p <0.001). Relatively fewer patients
between 16 and 24 years of age (7.69 vs 14.04%) and rela-
tively more patients between 25 and 44 years of age (34.85
vs 31.71%) or 45 and 64 years of age (34.14 vs 28.21%)
had been prescribed opioids. Opioid-naïve patients receiv-
ing opioids at the ED were predominantly walk-in patients
(57.06 vs 45.28%) and the majority of them (61.30 vs
57.18%) visited during the daytime (06:00–17:00). The
most prevalent designated chief complaints of patients re-
quiring an opioid prescription at the ED were muscu-
Figure 1: Patient inclusion and exclusion.
loskeletal problems, including rheumatological diseases
(37.23 vs 13.03%) and physical trauma (27.01 vs 14.57%)
(table 1).
Incident opioid prescription in opioid-naïve patients
The incidence of new opioid prescriptions was highest in
the first half of 2014, at 2.54% (2.31–2.77%), and lowest
in the first half of 2016 at 2.03% (1.84–2.22%) (fig. 2A,
supplementary table S1A in appendix 1). The chi-square
statistic for a linear trend showed a significant (p <0.001)
negative trend over the study period (slope −0.041% per
half year, standard error 0.012%, supplementary fig. S1A
in appendix 1). If the analysis was restricted to out-patients
only, the incidence for new prescriptions of opioids ranged
between 1.97 and 2.62% (fig. 2B). The trend towards a
decreased proportion of new opioid prescriptions was de-
scriptively less prominent and nonsignificant (p = 0.069)
in outpatients (slope −0.026% per half year, standard error
0.014%, fig. S1B) in the unadjusted analysis, although a
significant association between incident opioid prescrip-
tion and half year (p = 0.014) was found in outpatients
(table S1A).
For multivariable analysis the observed proportions were
adjusted for variables that had shown at least very weak
evidence (p <0.2) for an association with incident opioid
use (see table 1). In the adjusted analysis, there was a sig-
nificant association between incident opioid use and half
year in all patients (p = 0.002), as well as in outpatients (p
= 0.004), with significant linear decreasing trends both in
all patients (slope −0.049, standard error 0.012, p <0.001)
and in outpatients (slope −0.036, standard error 0.015%, p
= 0.016), see figs 2A and 2B.
Prevalent opioid use
The proportion of patients per half year with documented
opioid use on presentation over the study period is shown
in figure 3 (table S1B and fig. S2 in appendix 1). The
observed proportion ranged from 4.64% (95% CI
4.35–4.94%) in the second half of 2014 to 5.26% (95%
CI 4.97–5.56%) in the second half of 2017 and showed
a significant positive linear trend over time (p <0.001),
corresponding to an increase in prevalent opioid consul-
tations of about 0.06% per half year; see figure 3 (slope
0.058%, standard error 0.017%). In multivariable analysis,
the increasing linear trend over the study period could not
be confirmed (slope −0.001%, standard error 0.017, p =
0.736) as there was no significant association of the adjust-
ed proportions and half year (p = 0.163) after adjustment
for age group, trauma, the interaction of trauma and age
group, other chief complaints, type of admission, and time
of admission (fig. 3 and table S1B).
Discussion
In this sample, the average prevalence of opioid use was
around 5% and incident opioid use in opioid-naïve patients
was around 2.2%. The prevalence of opioid consumption
appears to be higher at the ED than in the general popula-
tion. For Europe, prevalence of opioid use was estimated
as 2.2% in 2017 and in 2016 [5], and a survey in 11,000
participants from the Swiss population over 15 years of
age indicated that 1.8% of the population used strong anal-
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Table 1: Patient characteristics according to incident opioid use (n = 199,299).
Newly prescribed opioid Total
(n = 199,299)
p-value
No
(n = 194,803)
Yes
(n = 4496)
Day of the week, n
(%)
Monday 29,108 (14.94) 675 (15.00) 29,783 (14.94) 0.240
Tuesday 26,519 (13.61) 586 (13.03) 27,105 (13.60)
Wednesday 26,604 (13.66) 617 (13.71) 27,221 (13.66)
Thursday 26,936 (13.83) 610 (13.56) 27,546 (13.82)
Friday 28,496 (14.63) 666 (14.80) 29,162 (14.63)
Saturday 29,445 (15.12) 648 (14.4) 30,093 (15.10)
Sunday 27,692 (14.22) 697 (15.49) 28,389 (14.24)
Time of admission, n
(%)
Day (06:00 to 17:00) 111,383 (57.18) 2758 (61.30) 114,141 (57.27) <0.001
Evening (17:00 to 22:00) 52,196 (26.79) 1048 (23.29) 53,244 (26.72)
Night (22:00 to 06:00) 31,221 (16.03) 693 (15.4) 31,914 (16.01)
Saturday or Sunday admission (00:00 to 23:59), n (%) 57,137 (29.33) 1345 (29.9) 58,482 (29.34) 0.411
Public and cantonal (Bern) holidays, n (%) 3927 (2.02) 107 (2.38) 4034 (2.02) 0.088
Effective weekends (19:00 Friday to 06:59 Monday), n
(%)
66,042 (33.90) 1553 (34.52) 67,595 (33.92) 0.388
Effective days off (Sat., Sun. and public holidays), n
(%)
59,876 (30.74) 1417 (31.5) 61,293 (30.75) 0.276
Triage, n (%) Life-threatening 15,058 (7.73) 283 (6.29) 15,341 (7.70) <0.001
Highly urgent 45,290 (23.25) 915 (20.34) 46,205 (23.18)
Urgent 113,839 (58.44) 3048 (67.75) 116,887 (58.65)
Semi-urgent 13,243 (6.80) 163 (3.62) 13,406 (6.73)
Non-urgent 3182 (1.63) 49 (1.09) 3231 (1.62)
Missing 4188 (2.15) 41 (0.91) 4229 (2.12)
Sex, n (%) Male 109,383 (56.15) 2557 (56.83) 111,940 (56.17) 0.361
Female 85,417 (43.85) 1942 (43.17) 87,359 (43.83)
Age group, n (%) 16–24 27,353 (14.04) 346 (7.69) 27,699 (13.90) <0.001
25–44 61,776 (31.71) 1568 (34.85) 63,344 (31.78)
45–64 54,961 (28.21) 1536 (34.14) 56,497 (28.35)
65–84 42,629 (21.88) 870 (19.34) 43,499 (21.83)
≥85 8081 (4.15) 179 (3.98) 8260 (4.14)
Type of referral, n (%) Walk-in 88,205 (45.28) 2567 (57.06) 90,772 (45.55) <0.001
Ambulance 28,576 (14.67) 705 (15.67) 29,281 (14.69)
External hospital 14,924 (7.66) 167 (3.71) 15,091 (7.57)
General practitioner 10,727 (5.51) 216 (4.80) 10,943 (5.49)
Internal referral 7382 (3.79) 99 (2.2) 7481 (3.75)
Air rescue 2388 (1.23) 115 (2.56) 2503 (1.26)
Police 2172 (1.11) 13 (0.29) 2185 (1.10)
Urgent care centre/doctor 1767 (0.91) 49 (1.09) 1816 (0.91)
Repatriation 305 (0.16) 12 (0.27) 317 (0.16)
Other 730 (0.37) 7 (0.16) 737 (0.37)
No information 37,624 (19.31) 549 (12.20) 38,173 (19.15)
Revisit in half year, n (%) 33,998 (17.45) 782 (17.38) 34,780 (17.45) 0.901
Chief complaint, n
(%)
Trauma 28,386 (14.57) 1215 (27.01) 29,601 (14.85) <0.001
Musculoskeletal including
rheumatological problems
25,379 (13.03) 1675 (37.23) 27,054 (13.57)
Neurological problem 22,918 (11.76) 233 (5.18) 23,151 (11.62)
Infectious disease, including
skin problems
13,377 (6.87) 172 (3.82) 13,549 (6.8)
Psychiatric problem, including
self-harm
12,836 (6.59) 9 (0.20) 12,845 (6.45)
Ear/nose/throat problems 12,188 (6.26) 109 (2.42) 12,297 (6.17)
Cardiovascular problem 11,811 (6.06) 201 (4.47) 12,012 (6.03)
Eye problem 11,968 (6.14) 0 (0.00) 11,968 (6.01)
Respiratory problem 6944 (3.56) 111 (2.47) 7055 (3.54)
Genitourinary problem 6160 (3.16) 162 (3.60) 6322 (3.17)
Follow up 4028 (2.07) 30 (0.67) 4058 (2.04)
Gastrointestinal problem 1375 (0.71) 38 (0.84) 1413 (0.71)
Dental problem 559 (0.29) 29 (0.64) 588 (0.30)
Obstetric or gynaecological
problem
20 (0.01) 0 (0.00) 20 (0.01)
Other 21,022 (10.79) 293 (6.51) 21,315 (10.69)
Missing 15,829 (8.13) 222 (4.93) 16,051 (8.05)
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Figure 2: Observed and adjusted relative numbers of incident opioid prescription, i.e., newly prescribed opioids in opioid-naïve patients (A) in
all patients, n = 199,299; (B) in outpatients, n = 134,468. The relative number per 6 months with accompanying 95% confidence interval and
linear trends are presented.
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gesics daily for at least 1 year [16]. This discrepancy is
most probably due to the difference in the population pro-
file of the ED when compared with the general population.
In 2013, incidental opioid use, as extrapolated from health
insurance data for the Swiss population, was 4.8% for at
least one weak opioid claim (with a morphine conversion
factor of 0.3 or less, namely codeine and combinations, ti-
lidine, tramadol and tapentadol) and 2.8% for at least one
strong opioid claim (defined as no weak opioid) [9]. Thus,
the average raw incidence of new prescriptions at the study
centre appears to be relatively low.
The proportions of patients consuming opioids on presen-
tation at the ED increased significantly over time, but the
linear trend of this increase was not robust to adjustment
for the identified confounders (age and diagnoses). Our da-
ta may support the findings of Gmel et al. [16] that use
of strong analgesics increased in Switzerland until 2015 –
especially in elderly patients. The patients using opioids
when visiting the ED may have become older and the inci-
dence of musculoskeletal pain possibly increased over the
years.
Incidental opioid prescriptions at the ED were analysed as
a quality assurance endpoint. It is promising that new opi-
oid prescriptions at the ED exhibited a significant slight-
ly decreasing trend in the logistic regression analysing all
ED patients, which was robust to adjustment for the detect-
ed covariables. On the other hand, this difference was out-
side the threshold of the 95% CI and the findings may have
been influenced by factors that were out of the scope of our
study. In any case, there was no significant increase.
Changes in ED prescription practice might not substan-
tially alter the prevalence of opioid use, as one retrospec-
tive analysis of the nationally representative Medical Ex-
penditure Panel Survey in the Unites States found that the
majority of the increase in opioid prescriptions between
1996 and 2012 was attributable to office visits and refills
of previously prescribed opioids, and only modestly due to
ED visits [17]. Thus, other sources of opioid prescription
should be additionally targeted in order to decrease opi-
oid use in the general population. Furthermore, the finding
that opioid prevalence and incidence are associated with
both age and disease in our sample raises the question as
to whether and to what extent opioid use is in fact rather
appropriate in our population and whether it presents any
real problem.
Limitations
There are several limitations that may influence the relia-
bility of the present results. Firstly, prevalent and inciden-
tal opioid use, as well as the relative number of additional
prescribed opioids, might be underestimated in the sample
owing to documentation bias, as missing documentation of
an opioid medication was handled as “no opioid medica-
tion”. Moreover, it is unclear what doses of opioids the pa-
tients consulting the ED had consumed and over what pe-
riod. Furthermore, the trend for less opioid prescriptions at
the ED may also be confounded by factors that were not
part of our analysis. For example, transfer policy within
the university clinic may have changed in such a way that
patients in need for hospitalisation were transferred to the
ward before treatment with strong analgesics at the ED.
Figure 3: Observed and adjusted relative number of opioid use on presentation (prevalent opioid use) including a linear trend. The relative
number per six months with accompanying 95% confidence interval are presented, n = 199,299.
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Secondly, the reason for consultation (“chief complaint”,
e.g., the principal symptom) does not cover all aspects of
the morbidity of the patient and was, at least in some pa-
tients, not linked to the opioid therapy taken. Thus, the
morbidity and health of the patient population may not
have been adequately described. Furthermore, the type,
dosage and duration of the opioid medication were not
considered in this analysis. This limits the usefulness of the
data in risk-benefit assessments on pain therapy at the ED
and may qualify conclusions regarding public health con-
cerns, such as non-medical use of prescription drugs.
Lastly, the conclusions are derived from a single centre
analysis of a university hospital, so the external validity
may be limited.
Safety aspects and future implications
The prescriptions were not associated with repeated visits
to the ED within 6 months. It can be assumed, however,
that patients subsequently visited healthcare institutions
other than the ED. In a nationwide cohort observation in
the United States, the Consortium to Study Opioid Risks
and Trends (CONSORT) found that 3–5.5% of patients
who had initiated opioid consumption because of acute
pain received long-term opioid therapy, defined as an
episode of use lasting at least 90 days with at least 10 pre-
scriptions and/or 120 days’ supply of opioids dispensed in
the episode [18]. Another study found that 68% of opioids
prescribed at the ED were left unused, and thus overpre-
scribing may be present and result in large quantities of un-
used opioids and possible misuse and dependency [1]. In
Switzerland, an average of 80 treatment days per person is
estimated for opioids [8] and daily use is strongly corre-
lated to older age as well as increased morbidity. Data on
the actual number of patients under long-term opioid ther-
apy or possibly inadequate prescriptions are unknown for
Switzerland – nor does our data analysis provide any esti-
mates of the duration and adequacy of the opioid therapy of
the patients under such therapy on presentation. Although
little is yet known about risk factors, optimal clinical as-
sessment and treatment approaches related to concurrent
chronic pain and substance misuse [19], it can be conclud-
ed that there are correlations between morbidity and opi-
oid-related death and daily dose [20, 21], as well as be-
tween risk of misuse and type of opioid medication [22,
23]. In particular, patients with an additional opioid pre-
scription might be at risk for misuse or opioid-related com-
plications, and additional opioids may not even be of ben-
efit [23, 24].
Adolescents may be another group at risk of opioid misuse.
It was found in a nationwide survey of young adults in
Switzerland that the self-reported non-medical use of opi-
oids was 6.1% in the cohort [9]. The authors investigated
patients at risk and found a correlation between users of
prescription drugs, and emotional and physical traumatic
events. Of all patients below 25 years of age visiting the
ED, 1.2% (95% CI 1.06–1.34%) received opioids during
their visit.
Although the numbers of opioid prescriptions had not risen
in this single-centre analysis, more specific data on the
type and dosage of opioids, as well as the patients at risk
for permanent non-medical use, are needed to assure good
clinical pain therapy [25]. This is especially important, be-
cause for outpatients the trend towards less opioid con-
sumption was not significant in our analysis. Instruments
like the Prescription Opioid Misuse Index (POMI) [26],
the Prescription Opioid Difficulties Scale (PODS) [27] or
the Prescription Drug Use Questionnaire (PDUQ) [28]
may be helpful for future investigations.
Conclusion
This analysis of the prevalence of opioid medication and
incident opioid prescriptions at the ED may be a first step
to improve quality of opioid prescription. Although preva-
lence remained stable and the incidence of prescriptions
between 2013 and 2017 has decreased after adjustment for
confounders, the results cannot be generalised, as they de-
rive from a single centre and there were many missing val-
ues. Further research should include patients’ profiles, pre-
scription details and longitudinal results.
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Appendix 1 Supplementary data
Table S1: Observed and adjusted proportions with 95% CI for (A) incident (newly prescribed) and (B) prevalent opioid medication on presentation, over the study period.
Observed Adjusted*
Proportion (95% CI)
(%)
p#/p+ Proportion (95% CI)
(%)
p#/p+
(A) Newly prescribed opioids
All patients 1st half of 2013 2.44 (2.21–2.67) 0.007/<0.001 2.64 (2.39–2.89) 0.002/<0.001
2nd half of 2013 2.43 (2.20–2.65) 2.63 (2.39–2.87)
1st half of 2014 2.54 (2.31–2.77) 2.65 (2.42–2.89)
2nd half of 2014 2.18 (1.97–2.39) 2.34 (2.12–2.56)
1st half of 2015 2.28 (2.07–2.48) 2.46 (2.24–2.68)
2nd half of 2015 2.26 (2.05–2.46) 2.37 (2.16–2.58)
1st half of 2016 2.03 (1.84–2.22) 2.18 (1.98–2.38)
2nd half of 2016 2.34 (2.14–2.55) 2.46 (2.25–2.67)
1st half of 2017 2.10 (1.91–2.29) 2.14 (1.95–2.34)
2nd half of 2017 2.09 (1.90–2.28) 2.28 (2.07–2.48)
Outpatients only 1st half of 2013 2.52 (2.23–2.80) 0.014/0.069 2.78 (2.46–3.10) 0.004/0.016
2nd half of 2013 2.26 (2.00–2.53) 2.53 (2.24–2.82)
1st half of 2014 2.43 (2.15–2.70) 2.64 (2.34–2.93)
2nd half of 2014 2.44 (2.18–2.71) 2.67 (2.39–2.96)
1st half of 2015 2.40 (2.14–2.66) 2.65 (2.37–2.94)
2nd half of 2015 2.30 (2.05–2.55) 2.51 (2.24–2.78)
1st half of 2016 1.97 (1.74–2.19) 2.17 (1.92–2.41)
2nd half of 2016 2.62 (2.36–2.88) 2.81 (2.53–3.08)
1st half of 2017 2.14 (1.90–2.38) 2.20 (1.96–2.45)
2nd half of 2017 2.19 (1.96–2.43) 2.45 (2.19–2.71)
B) Opioids at presentation
1st half of 2013 4.73 (4.42–5.05) 0.023/0.007 5.00 (4.67–5.33) 0.163/0.736
2nd half of 2013 4.97 (4.65–5.29) 5.37 (5.03–5.71)
1st half of 2014 4.65 (4.34–4.95) 4.79 (4.48–5.10)
2nd half of 2014 4.64 (4.35–4.94) 4.76 (4.46–5.06)
1st half of 2015 5.08 (4.77–5.38) 5.03 (4.73–5.33)
2nd half of 2015 4.79 (4.50–5.09) 4.71 (4.43 – 5.00)
1st half of 2016 4.96 (4.67–5.25) 4.90 (4.62–5.19)
2nd half of 2016 5.10 (4.81–5.39) 4.96 (4.68–5.25)
1st half of 2017 5.20 (4.90–5.50) 4.95 (4.67–5.23)
2nd half of 2017 5.26 (4.97–5.56) 5.08 (4.80–5.36)
* Adjusted for age group, trauma, the interaction of trauma and age group, other chief complaint, type of admission, and time of admission. # Of the chi-square test of the associ-
ation of opioids and half year. + Of the chi-square test for a linear trend.
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Figure S1: Incident opioid prescription, i.e., newly prescribed opioids in opioid-naïve patients (A) in all patients, n = 199,299; (B) in outpa-
tients, n = 134,468. The relative number per 6 months with accompanying 95% confidence interval and linear trend are presented. The chi-
square test for trend showed a (A) significant (p <0.001) and (B) nonsignificant (p = 0.069) decreasing trend over time.
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Figure S2: Prevalent opioid use at presentation. The relative number per 6 months with accompanying 95% confidence interval and linear
trend are presented, n = 199,299. The chi-square test for trend showed a significant increase over time (p <0.001).
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